• ACTH-Dependent Cushing’s Syndrome. research hub

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

This clinical study tests a new tablet called atumelnant for adults with ACTH-dependent Cushing's syndrome. In this condition, the body makes too much cortisol hormone. Researchers want to see if different doses of atumelnant can safely bring cortisol levels back to normal within 12 weeks and improve everyday wellbeing.